Generic Avelox
Active component:
MoxifloxacinPackages: 400 mg |
Avelox (Moxifloxacin) 400 mg buy online at our online pharmacy: | ||
Package | Price | Currency: |
---|---|---|
400 mg × 30 pills | $ 336.90 $ 263.90 $ 8.80 per pill | Buy Avelox 400 mg × 30 » |
400 mg × 20 pills | $ 224.90 $ 192.90 $ 9.64 per pill | Buy Avelox 400 mg × 20 » |
400 mg × 10 pills | $ 117.90 $ 111.90 $ 11.19 per pill | Buy Avelox 400 mg × 10 » |
We accept major debit cards, credit cards and pre-paid credit cards: Visa, MasterCard and other
Manufacturer: Cipla Limited
Avelox (Moxifloxacin) is a highly effective and widely used antibiotic that belongs to the fluoroquinolone class. It is primarily prescribed for the treatment of various bacterial infections, including respiratory tract infections, skin and soft tissue infections, urinary tract infections, and certain sexually transmitted diseases.
The remarkable potency of Avelox is attributed to its unique mechanism of action, which involves inhibiting the activity of bacterial enzymes responsible for DNA replication and repair. By disrupting these essential cellular processes, Avelox effectively eliminates the bacteria causing the infection, leading to a rapid resolution of symptoms.
One of the distinguishing features of Avelox is its exceptional spectrum of activity. It demonstrates high potency against a broad range of Gram-positive and Gram-negative bacteria, including notoriously challenging pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, and Staphylococcus aureus. This wide coverage ensures that Avelox can effectively combat a variety of infections, even those caused by multidrug-resistant strains.
Moreover, Avelox exhibits excellent tissue penetration, allowing it to reach and eradicate bacteria that reside in hard-to-reach areas. This characteristic is particularly advantageous for treating infections in deep tissues, such as osteomyelitis and intra-abdominal infections. Additionally, its favorable pharmacokinetic profile ensures convenient dosing regimens, usually administered orally once daily.
Avelox has been proven to be highly efficacious in numerous clinical trials. In a comprehensive study evaluating its effectiveness in treating community-acquired pneumonia, Avelox demonstrated superior clinical and bacteriological outcomes when compared to other commonly used antibiotics. Similar positive results have been observed in studies investigating its efficacy against other bacterial infections, further reinforcing its status as a leading choice among healthcare professionals.
In terms of safety, Avelox has a generally well-tolerated profile. The most commonly reported adverse reactions are mild and transient, including gastrointestinal disturbances like nausea, diarrhea, and abdominal pain. Serious adverse events are rare but may include tendon rupture, although cases of this occurrence have been extremely infrequent.
While Avelox is widely regarded as a reliable and effective antibiotic, it is important to exercise caution when prescribing this medication. Certain patient populations, such as individuals with a history of tendon disorders, should be monitored closely due to the potential risk of tendon rupture. Additionally, Avelox should be used judiciously to minimize the development of antibiotic resistance, which is a global health concern.
Avelox (Moxifloxacin) stands as a powerful and versatile antibiotic that plays a crucial role in the management of various bacterial infections. With its extensive spectrum of activity, convenient dosing regimens, and proven efficacy, Avelox remains a trusted choice among healthcare professionals. When prescribed judiciously and monitored carefully, Avelox provides an essential tool in the fight against bacterial infections, contributing to improved patient outcomes and overall public health.
The remarkable potency of Avelox is attributed to its unique mechanism of action, which involves inhibiting the activity of bacterial enzymes responsible for DNA replication and repair. By disrupting these essential cellular processes, Avelox effectively eliminates the bacteria causing the infection, leading to a rapid resolution of symptoms.
One of the distinguishing features of Avelox is its exceptional spectrum of activity. It demonstrates high potency against a broad range of Gram-positive and Gram-negative bacteria, including notoriously challenging pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, and Staphylococcus aureus. This wide coverage ensures that Avelox can effectively combat a variety of infections, even those caused by multidrug-resistant strains.
Moreover, Avelox exhibits excellent tissue penetration, allowing it to reach and eradicate bacteria that reside in hard-to-reach areas. This characteristic is particularly advantageous for treating infections in deep tissues, such as osteomyelitis and intra-abdominal infections. Additionally, its favorable pharmacokinetic profile ensures convenient dosing regimens, usually administered orally once daily.
Avelox has been proven to be highly efficacious in numerous clinical trials. In a comprehensive study evaluating its effectiveness in treating community-acquired pneumonia, Avelox demonstrated superior clinical and bacteriological outcomes when compared to other commonly used antibiotics. Similar positive results have been observed in studies investigating its efficacy against other bacterial infections, further reinforcing its status as a leading choice among healthcare professionals.
In terms of safety, Avelox has a generally well-tolerated profile. The most commonly reported adverse reactions are mild and transient, including gastrointestinal disturbances like nausea, diarrhea, and abdominal pain. Serious adverse events are rare but may include tendon rupture, although cases of this occurrence have been extremely infrequent.
While Avelox is widely regarded as a reliable and effective antibiotic, it is important to exercise caution when prescribing this medication. Certain patient populations, such as individuals with a history of tendon disorders, should be monitored closely due to the potential risk of tendon rupture. Additionally, Avelox should be used judiciously to minimize the development of antibiotic resistance, which is a global health concern.
Avelox (Moxifloxacin) stands as a powerful and versatile antibiotic that plays a crucial role in the management of various bacterial infections. With its extensive spectrum of activity, convenient dosing regimens, and proven efficacy, Avelox remains a trusted choice among healthcare professionals. When prescribed judiciously and monitored carefully, Avelox provides an essential tool in the fight against bacterial infections, contributing to improved patient outcomes and overall public health.
Technical Information
Brand names: Moxifloxacin HCl, Vigamox
Avelox: Moxicip (Cipla Limited)
Imprints: Avelox (moxifloxacin) BAYER M400